FDA Approves First Once-Monthly Buprenorphine Injection, a Medication-assisted Treatment Option for Opioid Use Disorder
FDA News Release
The U.S. Food and Drug Administration today approved Sublocade, the first once-monthly injectable buprenorphine product for the treatment of moderate-to-severe opioid use disorder (OUD) in adult patients who have initiated treatment with a transmucosal (absorbed through mucus membrane) buprenorphine-containing product. It is indicated for patients that have been on a stable dose of buprenorphine treatment for a minimum of seven...
Full Text: PDF
LumiText Publishing, P.O. Box 774, Ellicott City, MD 21041
Copyright © 2008 LumiText Publishing. All rights reserved.